Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, October 12, 2026 at 8:

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced five abstracts have been accepted for presentation at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting® 2026, being held November 5 – 9, 2026 in Denver, CO. The abstracts released today can be found on the AASLD website at https://www.aasld.org/the-liver-meeting.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, September 28, 2026 at

Aligos Therapeutics (NASDAQ: ALGS - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings. Institutional and Insider Ownership 60.4% of Aligos

Bank of America Corp DE grew its holdings in shares of Aligos Therapeutics, Inc. (NASDAQ: ALGS) by 1,652.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 229,754 shares of the company's stock after buying an additional 216,646 shares

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Cantor Global Healthcare Conference.

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing has been initiated in the Phase 1 study of ALG-170675, an investigational next-generation antisense oligonucleotide (ASO) being evaluated for functional cure in the treatment of chronic hepatitis B virus (HBV) infection. The study is being conducted in China by Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), who maintain rights in Greater China.

SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's second quarter 2026 financial results on Thursday, August 6, 2026, before the open of the U.S. financial markets.